Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.

Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A.

Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20864-9. doi: 10.1073/pnas.0808757105.

2.

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD.

Semin Oncol. 2006 Aug;33(4):513-20. Review.

PMID:
16890805
3.

Cancer target discovery using SAGE.

Porter D, Polyak K.

Expert Opin Ther Targets. 2003 Dec;7(6):759-69. Review.

PMID:
14640911
4.

Medicine. Building better mouse models for studying cancer.

Marx J.

Science. 2003 Mar 28;299(5615):1972-5. No abstract available.

PMID:
12663895
5.

Rational targeting of Notch signaling in cancer.

Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L.

Oncogene. 2008 Sep 1;27(38):5124-31. doi: 10.1038/onc.2008.226. Review.

PMID:
18758481
6.

Systems for identifying new drugs are often faulty.

Gura T.

Science. 1997 Nov 7;278(5340):1041-2. No abstract available.

PMID:
9381203
7.

Selective killing of cancer cells based on loss of heterozygosity and normal variation in the human genome: a new paradigm for anticancer drug therapy.

Basilion JP, Schievella AR, Burns E, Rioux P, Olson JC, Monia BP, Lemonidis KM, Stanton VP Jr, Housman DE.

Mol Pharmacol. 1999 Aug;56(2):359-69.

8.

Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.

Mizuarai S, Irie H, Schmatz DM, Kotani H.

Curr Mol Med. 2008 Dec;8(8):774-83. Review.

PMID:
19075675
9.
10.

Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock".

Sharma SV, Settleman J.

Biochem Pharmacol. 2010 Sep 1;80(5):666-73. doi: 10.1016/j.bcp.2010.03.001. Review.

PMID:
20211150
11.

Predicting drug response based on gene expression.

Robert J, Vekris A, Pourquier P, Bonnet J.

Crit Rev Oncol Hematol. 2004 Sep;51(3):205-27. Review.

PMID:
15331079
12.

The null oncogene hypothesis and protection from cancer.

Davenport MP, Ward RL, Hawkins NJ.

J Med Genet. 2002 Jan;39(1):12-4.

13.

Anti-cancer natural product library from traditional chinese medicine.

Konkimalla VB, Efferth T.

Comb Chem High Throughput Screen. 2008 Jan;11(1):7-15.

PMID:
18220539
14.

[Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].

Nishiyama M.

Gan To Kagaku Ryoho. 2005 Nov;32(12):1902-7. Review. Japanese.

PMID:
16282724
15.

Disruption of oncogene/tumor suppressor networks during human carcinogenesis.

M√ľnger K.

Cancer Invest. 2002;20(1):71-81. Review.

PMID:
11853005
16.

Molecular diagnostics of solid malignant tumours.

Brandt BH.

Clin Lab. 2002;48(11-12):605-15.

PMID:
12465745
17.

Identification of cancer genes by mutational profiling of tumor genomes.

Benvenuti S, Arena S, Bardelli A.

FEBS Lett. 2005 Mar 21;579(8):1884-90. Review.

18.

Cancers beget mutations versus mutations beget cancers.

Prehn RT.

Cancer Res. 1994 Oct 15;54(20):5296-300.

19.

Bibliography. Current world literature. Cancer biology.

[No authors listed]

Curr Opin Oncol. 2005 Jan;17(1):67-82. No abstract available.

PMID:
15810123
20.

Farnesyl transferase inhibitors.

Li T, Sparano JA.

Cancer Invest. 2008 Aug;26(7):653-61. doi: 10.1080/07357900801971016. No abstract available.

PMID:
18665473
Items per page

Supplemental Content

Support Center